Overview

Efficacy and Safety of Verteporfin Added to Ranibizumab in the Treatment of Symptomatic Macular Polypoidal Choroidal Vasculopathy

Status:
Completed

Trial end date:
1969-12-31

Target enrollment:

Participant gender:

Summary

This study aims to compare the efficacy of ranibizumab and verteporfin PDT combination treatment and verteporfin PDT monotherapy vs.ranibizumab monotherapy alone in achieving complete regression of polyps in patients with symptomatic macular polypoidal choroidal vasculopathy.

Phase:

Phase 4

Details

Lead Sponsor:

Novartis

Treatments:

Ranibizumab
Verteporfin